VCIM
VRCA icon

Velan Capital Investment Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Velan Capital Investment Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Hold
471,559
– – 1.56% 18
2025
Q4 		$3.92M Buy
+471,559
New +$2.61M 2.27% 13

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Velan Capital Investment Management's VRCA Position: Q1 2026 in Review

Velan Capital Investment Management held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 471,559 shares worth $2.49M. The position accounts for 1.56% of the portfolio, ranked #18.

Velan Capital Investment Management first reported a position in VRCA in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.92M in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Velan Capital Investment Management held 471,559 shares of Verrica Pharmaceuticals worth $2.49M as of Q1 2026.
  • Velan Capital Investment Management left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
  • Verrica Pharmaceuticals made up 1.56% of Velan Capital Investment Management's portfolio in Q1 2026, its #18 holding.
  • Velan Capital Investment Management first reported a position in Verrica Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Velan Capital Investment Management's Verrica Pharmaceuticals position peaked at $3.92M in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.